Is Cullinan Therapeutics, Inc. (CGEM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 42.9% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.2% / 33% | 42.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.3% / 33% | 64.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 42.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.3% / 33% | 64.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -44.0% | |
| Return on Assets (ROA) | -28.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$176M |
| Free Cash Flow | -$176M |
| Total Debt | $3M |
| Debt-to-Equity | 0.7 |
| Current Ratio | 10.2 |
| Total Assets | $448M |
Price & Trading
| Last Close | $13.67 |
| 50-Day MA | $13.22 |
| 200-Day MA | $9.54 |
| Avg Volume | 759K |
| Beta | -0.2 |
|
52-Week Range
$5.68
| |
About Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cullinan Therapeutics, Inc. (CGEM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cullinan Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cullinan Therapeutics, Inc.'s debt ratio?
Cullinan Therapeutics, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.3%.
What are Cullinan Therapeutics, Inc.'s key financial metrics?
Cullinan Therapeutics, Inc. has a market capitalization of $778M. Return on equity stands at -44.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.